Zydus Cadila Plans Indian Remdesivir Entry In July

Interferon Studies In Mexico, IND in US

Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.

Remdesivir
Zydus Cadila - Another Remdesivir Contender In The Wings • Source: Shutterstock

Zydus group's Cadila Healthcare hopes to launch its version of Gilead Sciences’ investigational COVID-19 drug remdesivir in India by end-July, even as other early licensees Cipla and Hetero Drugs have just introduced the formulation in the country. Marketing approval for Zydus Cadila's brand of remdesivir is expected by mid-July.

Meanwhile, the company’s other COVID-19 candidates - a DNA vaccine and pegylated interferon alpha-2b - are also being fast-tracked.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business